Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Argos Therapeutics

- PMLiVE

Cancer Research UK calls on government to create ten-year cancer plan

The charity estimates that around 20,000 annual cancer deaths in the UK could be prevented by 2040

The problem with clinical trials (and how virtual insight-gathering can help)

While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access.

Impetus Digital

- PMLiVE

UK government and NIHR accelerate plans to improve clinical research delivery

The government has created a focused plan for action to transform UK clinical research

- PMLiVE

Innovative Trials at the 2023 Lloyds Bank British Business Excellence Awards

Innovative Trials achievements recognized at the Lloyds Bank British Business Excellence Awards

Innovative Trials

- PMLiVE

AstraZeneca gains rights to Usynova’s KRAS inhibitor in deal worth almost $420m

There are currently no approved drugs specifically targeting the KRAS G12D mutation

- PMLiVE

Boehringer Ingelheim to acquire T3 Pharmaceuticals in deal worth over $500m

The acquisition marks a significant boost to Boehringer’s immuno-oncology portfolio

EU flag

EC approves pharmaand’s Rubraca as advanced ovarian cancer maintenance treatment

An estimated 66,000 new cases of ovarian cancer are diagnosed in Europe each year

- PMLiVE

ABPI report shows improvement in UK industry clinical trial performance

The data showed a 15% increase in annual recruitment to UK industry clinical trials

- PMLiVE

Pfizer and Astellas’ Xtandi approved by FDA for earlier prostate cancer indication

Xtandi is the first androgen receptor signalling inhibitor approved for this patient population

- PMLiVE

Merck receives FDA approval for Keytruda combination in gastric cancer

An estimated 26,500 people in the US will be diagnosed with gastric cancer in 2023

- PMLiVE

Bristol Myers Squibb’s lung cancer drug Augtyro receives FDA approval

The drug was added to BMS’ portfolio last year through its $4.1bn acquisition of Turning Point

- PMLiVE

Novartis gains global rights to Legend’s CAR-T cell therapies in deal worth over $1bn

Novartis can apply its T-Charge platform to the manufacturing process of the therapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links